儿童四肢骨肿瘤患者的手术治疗与结局:PARITY试验数据的二次分析
该研究为PARITY试验的儿童亚组二次分析,纳入151例≤18岁四肢骨肿瘤患者,随机接受术后5天或1天抗生素预防,1年内浅表或深部手术部位感染(SSI)发生率分别为17.9%,两组无显著差异(HR 0.92,95%CI 0.4-1.9,P=0.82)。肿瘤学结局两组亦无显著差异(HR 0.97,95%CI 0.5-1.8,P=0.92)。
要点
- 儿童骨肿瘤假体置换术后1年内SSI发生率为17.9%,5天与1天抗生素组无显著差异(HR 0.92,95%CI 0.4-1.9,P=0.82)。
- 术后1年内29.8%患者需再次手术,感染为最常见原因(29/45,64.4%),1年无再手术生存率为68.8%。
- 术后1年内转移23.8%、局部复发4.0%、死亡7.3%、截肢4.6%、假体翻修4.0%,肿瘤学结局两组无显著差异(HR 0.97,95%CI 0.5-1.8,P=0.92)。
核心结论
- 在PARITY试验中,儿童患者假体置换术后接受1天与5天抗生素方案的感染及肿瘤学结局均无显著差异。
研究设计与样本
- PARITY试验的二次分析,纳入PARITY试验中所有≤18岁、因骨肿瘤或软组织肉瘤侵犯股骨或胫骨需行骨切除和假体置换的患者,随机分为术后5天或1天抗生素预防组。
主要发现
- 共纳入151例患者,发生裁定SSI者27例(17.9%),5天组与1天组SSI发生率无差异(HR 0.92,95%CI 0.4-1.9,P=0.82)。
- 抗生素相关并发症13例(8.6%),两组无差异(HR 0.46,95%CI 0.2-1.4,P=0.18)。
- 45例(29.8%)术后1年内需重返手术室,考虑竞争风险后1年无再手术生存率为68.8%,再次手术最常见原因为感染(29/45,64.4%)。
- 7例(4.6%)需截肢,6例(4.0%)需假体翻修,36例(23.8%)发生转移,6例(4.0%)局部复发,11例(7.3%)死亡。
- 5天组与1天组肿瘤学结局无显著差异(HR 0.97,95%CI 0.5-1.8,P=0.92)。
关键数值与推荐
- SSI发生率:5天组 vs 1天组 HR 0.92(95%CI 0.4-1.9,P=0.82),无显著差异。
- 抗生素相关并发症:5天组 vs 1天组 HR 0.46(95%CI 0.2-1.4,P=0.18),无显著差异。
- 肿瘤学结局:5天组 vs 1天组 HR 0.97(95%CI 0.5-1.8,P=0.92),无显著差异。
临床怎么用
- 作者指出,外科医生应知晓并向患者及照护者告知术后1年内约30%的再手术率以及感染(17.9%)、死亡(7.3%)、截肢(4.6%)和假体翻修(4%)的风险。
局限性
- 证据等级为治疗性III级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Osteosarcoma and Ewing sarcoma are the 2 most common primary bone sarcomas, occurring predominantly in pediatric patients, with the incidence of osteosarcoma correlating with periods of peak bone-growth velocity. Although survival outcomes have plateaued over the past several decades, ongoing treatment advances have improved function, decreased infection rates, and improved other clinical outcomes in patients with bone tumors. Recently, the Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) trial addressed the serious problem of surgical site infection (SSI) and the lack of consensus regarding the appropriate prophylactic postoperative antibiotic regimen. The objective of the present secondary analysis of the PARITY trial was to characterize the modern treatment and surgical and oncologic outcomes of pediatric patients with bone tumors at 1 year postoperatively. METHODS: The PARITY trial included patients ≥12 years old with a bone tumor or soft-tissue sarcoma that was invading the femur or tibia, necessitating osseous resection and endoprosthetic reconstruction. This pediatric subanalysis of the PARITY trial data included all PARITY patients ≤18 years old. As in the main PARITY study, patients were randomized to either a 5-day or 1-day course of postoperative antibiotic prophylaxis. The primary outcome measure was the development of an SSI within 1 year, and secondary outcomes included antibiotic-related adverse events, unplanned additional operations, local recurrence, metastasis, and death. RESULTS: A total of 151 patients were included. An adjudicated SSI occurred in 27 patients (17.9%). There was no difference in the rate of any SSI between the 5-day and 1-day antibiotic groups (hazard ratio [HR], 0.92; 95% confidence interval [CI], 0.4 to 1.9; p = 0.82). Antibiotic-related complications occurred in 13 patients (8.6%), with no difference noted between groups (HR, 0.46; 95% CI, 0.2 to 1.4; p = 0.18). A total of 45 patients (29.8%) required a return to the operating room within the first postoperative year, which corresponded with a 68.8% reoperation-free rate of survival at 1 year when accounting for competing risks. The most common reason for reoperation was infection (29 of 45; 64.4%). A total of 7 patients (4.6%) required subsequent amputation of the operative extremity, and an additional 6 patients (4.0%) required implant revision within 12 months. A total of 36 patients (23.8%) developed metastases, and 6 patients (4.0%) developed a local recurrence during the first postoperative year. A total of 11 patients (7.3%) died during the study period. There were no significant differences in oncologic outcomes between the 5-day and 1-day antibiotic groups (HR, 0.97; 95% CI, 0.5-1.8; p = 0.92). CONCLUSIONS: There were no significant differences in surgical or oncologic outcomes between pediatric patients who underwent a 1-day versus 5-day antibiotic regimen following endoprosthetic reconstruction in the PARITY trial. Surgeons should be aware of and counsel patients and caregivers regarding the 30% rate of reoperation and the risks of infection (17.9%), death (7.3%), amputation (4.6%), and implant revision (4%) within the first postoperative year. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
引用
- Bozzo A, Yeung CM, Van De Sande M, et al. Operative Treatment and Outcomes of Pediatric Patients with an Extremity Bone Tumor: A Secondary Analysis of the PARITY Trial Data. J Bone Joint Surg Am. 2023. PMID: 37466582. doi:10.2106/JBJS.22.01231
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。